Tempest Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $13.4M
- Price
- $0.7926
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.29%
- Volume
- 156.5K
About
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
Quick stats
Shares outstanding16.9M
Computed float8.4M
Float / shares49.7%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001544227
Websitehttps://www.tempesttx.com
AI Summary
AI-generated1/16
minorneutralboard change
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
Tempest Therapeutics appointed Nancy Freda-Smith to its board of directors, where she will serve as Chair of the Audit Committee.
She brings over 30 years of finance and governance experience, most recently as Chief Audit and Risk Officer at Ralph Lauren and previously as an audit committee member at Chuy's Holdings through its acquisition by Darden Restaurants.
CEO Matt Angel highlighted her expertise in corporate governance, global finance, and enterprise risk management as adding value to the clinical-stage in vivo CAR-T company.
Red flags
- disclosed need for additional capital; going-concern risk referenced in forward-looking statements